The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CGC | -70% | -99.6% | -66.76% | -96% |
| S&P | +14.18% | +88.25% | +13.47% | +271% |
Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $48.42M | 4.8% |
| Gross Profit | $12.25M | 5.6% |
| Gross Margin | 25.30% | 0.2% |
| Market Cap | $455.51M | 11.4% |
| Market Cap / Employee | $0.47M | 0.0% |
| Employees | 960 | -6.7% |
| Net Income | -$1.19M | 98.8% |
| EBITDA | -$5.19M | 34.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $214.21M | 26.7% |
| Accounts Receivable | $17.65M | -34.7% |
| Inventory | 73.6 | 10.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $175.99M | -45.2% |
| Short Term Debt | $10.39M | -92.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.45% | 7.6% |
| Return On Invested Capital | -71.92% | -10.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.98M | 66.3% |
| Operating Free Cash Flow | -$13.09M | 66.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.68 | 0.29 | 0.66 | 0.84 | -16.62% |
| Price to Sales | 1.50 | 0.74 | 1.18 | 2.01 | -1.16% |
| Price to Tangible Book Value | 0.94 | 0.37 | 0.91 | 1.14 | -16.36% |
| Enterprise Value to EBITDA | -78.20 | 58.60 | -61.27 | -70.82 | -18.85% |
| Return on Equity | -84.5% | -122.1% | -98.4% | -60.2% | -34.83% |
| Total Debt | $340.48M | $242.07M | $240.24M | $186.38M | -58.96% |
One of the marijuana industry’s pioneers was just ousted from Canopy Growth. What comes next?
Bruce Linton talks with us about running the biggest pure-play marijuana company, and the future of the marijuana industry.
CGC earnings call for the period ending December 31, 2024.
CGC earnings call for the period ending September 30, 2024.
CGC earnings call for the period ending June 30, 2024.
CGC earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
